Phase 3 Stroke Trial, Recruiting NCT04667078 Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT04667078
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 to 80 years old
  • People who have had a blockage in a large artery supplying the front part of the brain (confirmed by a special type of brain scan called a CTA or MRA)
  • People whose stroke symptoms started less than 24 hours before the brain scan was taken
  • People whose brain scans show a specific pattern where the area of dead brain tissue is small compared to the area of brain tissue at risk — measured using specialised imaging software (confirm with trial site for exact scan requirements)
  • People who were largely independent before their stroke, with little to no disability beforehand
  • People with a stroke severity score of 6 or higher on a standard medical scale (NIHSS), indicating at least a moderate stroke

Who may not be able to join:

  • People for whom the standard mechanical clot removal procedure (thrombectomy) is not suitable
  • People over 80 years old who have more than 10 small areas of old bleeding visible on a pre-treatment brain MRI
  • People who were already significantly dependent or disabled before the stroke
  • People with a known blockage in both the neck and brain arteries that would require a stent to treat
  • People whose brain scans show a large area of already damaged brain tissue (below a specific score on a standard imaging scale)
  • People with a known allergy to the study drug (cangrelor) or any of its ingredients, including mannitol or sorbitol
  • People with a history of bleeding inside the brain
  • People showing signs of active bleeding or a broken bone from a recent injury at the time of examination
  • People who have recently had surgery that carries a significant risk of bleeding
  • People taking a blood-thinning medication called a VKA (such as warfarin) with a blood test result showing it is too active (INR above 1.7)
  • People who have taken certain blood-thinning medications (heparin or direct oral anticoagulants) in the past 48 hours, where blood test results show the medication is still significantly active in the body
  • People with a low platelet count (below 100,000 per mm³), meaning the blood may not clot properly
  • Women of childbearing age who have not had a pregnancy test, or who have tested positive for pregnancy
  • People who are under a legal protection order (confirm with trial site)
  • People who are not covered by a national health insurance scheme
  • People who have not given their consent to participate — or, in urgent situations, whose nominated trusted person has objected on their behalf
  • People already taking part in another stroke treatment study that could interfere with this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 01 48 03 65 65

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Registry
ClinicalTrials.gov
Start date
2 March 2022
Est. completion
1 March 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Favorable functional evaluation at 3 month for patients with acute ischemic strocke treated by cangrelor.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov